Stellettin B Sensitizes Glioblastoma to DNA‐Damaging Treatments by Suppressing PI3K‐Mediated Homologous Recombination Repair

Glioblastoma (GBM) is the most aggressive type of cancer. Its current first‐line postsurgery regimens are radiotherapy and temozolomide (TMZ) chemotherapy, both of which are DNA damage‐inducing therapies but show very limited efficacy and a high risk of resistance. There is an urgent need to develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Xin, Zhang, Shaolu, Wang, Yingying, Zhou, Zhicheng, Yu, Zixiang, Zhong, Zhenxing, Zhang, Liang, Chen, Zhe‐Sheng, Claret, Francois X., Elkabets, Moshe, Wang, Feng, Sun, Fan, Wang, Ran, Liang, Han, Lin, Hou‐Wen, Kong, Dexin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875605/
https://www.ncbi.nlm.nih.gov/pubmed/36453577
http://dx.doi.org/10.1002/advs.202205529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875605/
https://www.ncbi.nlm.nih.gov/pubmed/36453577
http://dx.doi.org/10.1002/advs.202205529

Ejemplares similares